Treatment and Management of Neurofibromatosis 1

Neurofibromatosis 1 is a common condition with an autosomal dominant pattern of inheritance. Clinical management of patients with NF1 is complex due to the diversity of symptoms within patients. An

[1]  R. Friedrich,et al.  Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children. , 2007, Anticancer research.

[2]  D. Gutmann,et al.  Optic pathway gliomas in neurofibromatosis‐1: Controversies and recommendations , 2007, Annals of neurology.

[3]  Kathryn N North,et al.  Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. , 2006, Developmental medicine and child neurology.

[4]  D. Evans,et al.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 , 2006, Journal of Medical Genetics.

[5]  E. Boltshauser,et al.  Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1. , 2006, The Journal of pediatrics.

[6]  D. Evans,et al.  Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Kluwe,et al.  Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1 , 2006, Journal of Medical Genetics.

[8]  In Ho Choi,et al.  Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. , 2006, The Journal of bone and joint surgery. American volume.

[9]  L. Sobin,et al.  Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis 1: A Clinicopathologic and Molecular Genetic Study of 45 Cases , 2006, The American journal of surgical pathology.

[10]  L. Kluwe,et al.  MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1 , 2006, Neuroradiology.

[11]  R. Buchert,et al.  Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  S. Störkel,et al.  Decreased bone mineral density in patients with neurofibromatosis 1 , 2005, Osteoporosis International.

[13]  S. Huson,et al.  Psychological disturbance and sleep disorders in children with neurofibromatosis type 1. , 2005 .

[14]  R. Schmelzle,et al.  Resection of small plexiform neurofibromas in neurofibromatosis type 1 children , 2005, World journal of surgical oncology.

[15]  R. Kortmann,et al.  Low Grade Chiasmatic-Hypothalamic Glioma - Carboplatin and Vincristin Chemotherapy Effectively Defers Radiotherapy within a Comprehensive Treatment Strategy , 2004, Klinische Padiatrie.

[16]  K. North,et al.  Social skills of children with neurofibromatosis type 1 , 2004, Developmental medicine and child neurology.

[17]  L. Kluwe,et al.  Treatment of ADHD in neurofibromatosis type 1 , 2002, Developmental medicine and child neurology.

[18]  D. Gutmann,et al.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. , 2002, Cancer research.

[19]  J. Friedman,et al.  Growth in North American white children with neurofibromatosis 1 (NF1) , 2000, Journal of medical genetics.

[20]  A. King,et al.  Malignant peripheral nerve sheath tumors in neurofibromatosis 1. , 2000, American journal of medical genetics.

[21]  J. Finlay,et al.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. , 1997, Journal of neurosurgery.

[22]  B. Korf.  Diagnostic outcome in children with multiple café au lait spots. , 1992, Pediatrics.